Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 6/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 6/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 6/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD5 | P21918 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6664631 | 0.99 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL10480295 | 0.97 | ADRA2A (0.95) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL6660860 | 0.87 | ADRA2A (0.77) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9375576 | 0.85 | ADRA2A (0.73) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9379441 | 0.84 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL9375551 | 0.84 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9769667 | 0.84 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL9385077 | 0.83 | ADRA2A (0.70) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL9385082 | 0.83 | ADRA2A (0.70) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9380183 | 0.82 | ADRA2A (0.75) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0344979-B1 | Alfa-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1994-11-09 | — | — | EP | claimed |
| EP-0344981-B1 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1994-08-03 | — | — | EP | claimed |
| US-4963547-A | HYPOTENSIVE AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-10-16 | — | — | US | claimed |
| WO-1989012054-A1 | alpha-ADRENERGIC RECEPTOR ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-12-14 | — | — | WO | claimed |
| EP-0344979-A2 | Alfa-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-12-06 | — | — | EP | claimed |
| EP-0344981-A2 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-12-06 | — | — | EP | claimed |
| US-20070219213-A1 | Use of Adrenergic N-Phenylpiperazine Antagonists, Pahrmaceutical Compositions Containning Them, and Methods of Preparing Them | UNIAO BRASILIENSE DE EDUCACAO E CULTURA-UBEC (BR) | 2007-09-20 | — | — | US | disclosed |
| EP-0344979-B1 | Alfa-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1994-11-09 | — | — | EP | disclosed |
| US-4963547-A | HYPOTENSIVE AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-10-16 | — | — | US | disclosed |
| WO-1989012054-A1 | alpha-ADRENERGIC RECEPTOR ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-12-14 | — | — | WO | disclosed |
| EP-0344979-A2 | Alfa-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219213-A1 | Use of Adrenergic N-Phenylpiperazine Antagonists, Pahrmaceutical Compositions Containning Them, and Methods of Preparing Them | ADRA1D, ADRB1, ADRA1A | ADRA2A 7/4885ADRA2B 8/4885ADRA2C 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.